VANCOUVER, BC and MESA, AZ, July 10, 2013 /PRNewswire/ - Avidus Management Group Inc. ("Avidus" or the "Company") (TSX-V: AVD, OTC: ASNHF) and its wholly owned subsidiary, Asantae, Inc. today announced the details of its new functional beverage, IS2.
IS2 is a specialized, proprietary formula that uses high potency extracts and bioavailable nutrients including Astralagus, Curcumin, and Resveratrol to support the body's natural ability to protect, fight, and rebuild against the effects of injury, illness, and disease.
The IS2 formula uses research done at many of the top nutraceutical and nutritional institutes in North America to identify the specific dosages and combinations needed to provide optimal benefits.
Dan Lundell, CEO said, "We are very excited about the launch of this revolutionary beverage this fall. We are confident that this product will provide significant health benefits and create excitement within our network that will accelerate recruiting and revenue growth. Mr. Ridley's experience and prior success within the functional beverage category make this product launch an exciting strategic growth opportunity as well as a natural extension of our mission to fight the root causes of disease."Doug Ridley, President, added, "Having built a company from the ground up, and led a successful network of distributors that generated annual sales of over $25 million, both focused on a functional beverage product, I am thrilled about the pending launch of IS2. The functional beverage space represents an enormous opportunity and we expect IS2 to drive our intensive recruitment and growth initiatives." About Avidus Avidus Management Group Inc. ( www.asantae.com) (TSX-V: AVD, OTC: ASNHF) through its wholly owned subsidiary, Asantae, Inc. develops, produces and markets innovative nutritional products through direct and network marketing channels. The ingredients in Avidus' products have been shown to reduce chronic low-grade inflammation and oxidative stress, and support a healthy immune system that, according to scientific and medical research, are the underlying conditions for most modern epidemic diseases (diabetes, heart disease, obesity, stroke, etc.). This news release may contain forward-looking statements relating to the Company's operations or to the environment in which it operates. Such statements are based on operations, estimates, forecasts and projections. They are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and may be beyond the Company's control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements, including those set forth in the Company's regulatory filings. In addition, such statements relate to the date on which they are made and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, save and except as may be required by applicable securities laws.